Table 1.
Author | Method | Patient no. | FLMT | Comorbidity | DM | Age | Male sex | Tobacco use | Blood pressure | CRP | Technique failure | Death |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Graff et al. [19] | TERalb | 39 | + | |||||||||
Heaf et al. [4] | JvL | 155 | + | + | No | + | + | (+) | + | |||
Van Biesen et al. [7] | JvL | 135 | + | + | +* | |||||||
Perl et al. [5] | Protein clearance | 192 | + | PVD + Pulse pressure | No | + | + | + | ||||
Balafa et al. [6] | Albumin clearance and loss | 257 | + | PVD | No | No | No | |||||
Dong et al. [8] | Protein clearance | 216 | + | + | No | + | No | + | + | +* | ||
Sanchez- Villanueva et al. [9] | Protein clearance | 133 | + | PVD | No | No | ||||||
Szeto et al. [10] | Albumin loss | 45 | + | Atherosclerosis | + | + | (+) |
FLMT, fast low-molecular transport; DM, diabetes mellitus; CRP, C-reactive protein; PVD, peripheral vascular disease; JvL, large-pore peritoneal clearance; +, positive correlation; *Correlation independent of low-molecular transport status. (), insignificant trend.